Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
131M
-
Number of holders
-
215
-
Total 13F shares, excl. options
-
58.2M
-
Shares change
-
-3.89M
-
Total reported value, excl. options
-
$493M
-
Value change
-
-$32.6M
-
Put/Call ratio
-
0.65
-
Number of buys
-
98
-
Number of sells
-
-89
-
Price
-
$8.47
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q2 2025
257 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q2 2025.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 215 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.2M shares
of 131M outstanding shares and own 44.54% of the company stock.
Largest 10 shareholders include TANG CAPITAL MANAGEMENT LLC (10M shares), BlackRock, Inc. (7.69M shares), NEA Management Company, LLC (3.97M shares), STATE STREET CORP (2.8M shares), MORGAN STANLEY (2.4M shares), VANGUARD GROUP INC (1.72M shares), ARMISTICE CAPITAL, LLC (1.63M shares), GEODE CAPITAL MANAGEMENT, LLC (1.58M shares), Qube Research & Technologies Ltd (1.24M shares), and RENAISSANCE TECHNOLOGIES LLC (1.16M shares).
This table shows the top 215 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.